New MDR TB drugs to hit market in 4-5 years
New drugs for multi-drug resistant tuberculosis that are expected to shorten the duration of treatment will be available in four to five years time.
By PTI |
MUMBAI: New drugs for multi-drug resistant (MDR) tuberculosis that are expected to shorten the duration of treatment will be available in four to five years time, an expert has said.
"It will take at least four to five years for the drugs of MDR tuberculosis to hit the market. The drugs are expected to shorten the treatment period to two to three months from the current eight to ten months," senior scientist at the Tuberculosis Research Centre, Chennai, Shaheed Jawahar said.
"Several companies have begun their research under the aegis of Global Alliance for new TB drug development and are at different stages of trials," Jawahar said at the three-day International Conference on 'Contemporary issues and future challenges in drug development,' of South Asian Chapter of American College of Clinical Pharmacology (SSCACCP) which concluded on Sunday.
Even the existing drugs which are undergoing trials to shorten the duration of treatment of MDR will also take another two to three years, he said.
"TB is a big public health problem and mostly poor people are affected by it. Therefore, no new drugs were developed in last 40 years. However, with the advent of HIV/AIDS, it is assuming great importance as it affects all sections of society and the new drug development is justified for multi-billion dollar business houses," he said.
The revised TB control programme under DOT strategies for ordinary patients in the country has been successful as compared to the older one, he said.
The challenges remain for the MDR TB and "we hope to have all the drugs in place in the next few years," he added.
Meanwhile, Maharashtra government's review of statistics of children affected with malnutrition has shown that 50 per cent of severely malnourished children had TB.
Women and Child Development Secretary Vijay Satbir Singh admitted that the figure was abnormally high. The strategies are being chalked out by the government to better combat malnutrition and would focus on TB in these children, he added.
Earlier, commenting on `Government initiatives for drugs and pharmaceuticals R and D in India,' Department of Science and Technology (DST) Advisor Dr G J Samathanam said Indian pharma industry will have to quickly move away from manufacturing only known drugs to innovative process routes for commercialising new molecules.
He also said the accumulated knowledge of traditional medicinal system and large bio-diversity of Indian sub-continent offer a great advantage to drug industry.
"Although at present, the small drug firms are not in a position to invest in new drug development, it is important for them to collaborate with academic institutions and national laboratories which have established impressive infrastructure and developed excellent expertise in selected areas of drug development," he said.
"It will take at least four to five years for the drugs of MDR tuberculosis to hit the market. The drugs are expected to shorten the treatment period to two to three months from the current eight to ten months," senior scientist at the Tuberculosis Research Centre, Chennai, Shaheed Jawahar said.
"Several companies have begun their research under the aegis of Global Alliance for new TB drug development and are at different stages of trials," Jawahar said at the three-day International Conference on 'Contemporary issues and future challenges in drug development,' of South Asian Chapter of American College of Clinical Pharmacology (SSCACCP) which concluded on Sunday.
Even the existing drugs which are undergoing trials to shorten the duration of treatment of MDR will also take another two to three years, he said.
"TB is a big public health problem and mostly poor people are affected by it. Therefore, no new drugs were developed in last 40 years. However, with the advent of HIV/AIDS, it is assuming great importance as it affects all sections of society and the new drug development is justified for multi-billion dollar business houses," he said.
The revised TB control programme under DOT strategies for ordinary patients in the country has been successful as compared to the older one, he said.
ADVERTISEMENT
The challenges remain for the MDR TB and "we hope to have all the drugs in place in the next few years," he added.
Meanwhile, Maharashtra government's review of statistics of children affected with malnutrition has shown that 50 per cent of severely malnourished children had TB.
Women and Child Development Secretary Vijay Satbir Singh admitted that the figure was abnormally high. The strategies are being chalked out by the government to better combat malnutrition and would focus on TB in these children, he added.
Earlier, commenting on `Government initiatives for drugs and pharmaceuticals R and D in India,' Department of Science and Technology (DST) Advisor Dr G J Samathanam said Indian pharma industry will have to quickly move away from manufacturing only known drugs to innovative process routes for commercialising new molecules.
ADVERTISEMENT
He also said the accumulated knowledge of traditional medicinal system and large bio-diversity of Indian sub-continent offer a great advantage to drug industry.
"Although at present, the small drug firms are not in a position to invest in new drug development, it is important for them to collaborate with academic institutions and national laboratories which have established impressive infrastructure and developed excellent expertise in selected areas of drug development," he said.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
